Coherus and Superior Biologics Announce National : vimarsana

First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of...

Related Keywords

Canada , United States , Hidradenitis Suppurativa , Denny Lanfear , Coherus Biosciences , Peter Fricke , John Brandt , Marek Ciszewski , Robert Cappa , Exchange Commission On , Nasdaq , Utilization Review Accreditation Commission , Rokk Solutions , Exchange Commission , Accreditation Commission For Healthcare , Coherus Biosciences Inc , Biologics Inc , Superior Biologics , Coheru Chairman , Chief Executive , Idiopathic Arthritis , Full Prescribing , Full Prescribing Information , Boxed Warning , Biologics License Application , Joint Commission , Accreditation Commission , Private Securities Litigation Reform Act , Coheru Quarterly Report , Contact Information , Biologics Contact , Nasdaq Chrs , Nc , Yusimry , Coherus , Humira , Adalimumab ,